NDAOPHTHALMICOINTMENT
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHLOROMYXIN is a fixed-dose ophthalmic ointment combining chloramphenicol and polymyxin B sulfate for topical ocular use. This combination targets bacterial eye infections through dual mechanisms of action: chloramphenicol inhibits bacterial protein synthesis while polymyxin B disrupts bacterial cell membranes. The product is indicated for treating bacterial conjunctivitis and other ocular infections.
Pre-Launch
Pre-launch stage indicates active commercial planning and team expansion; opportunity to shape go-to-market strategy and establish market position in the competitive ophthalmic space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining CHLOROMYXIN at pre-launch offers the rare opportunity to build a brand from inception, shape commercial strategy, and establish market presence in the specialized ophthalmic segment. However, career trajectory depends heavily on successful launch execution and competitive differentiation in a crowded generic-prone category.
Brand ManagerField Sales Representative
Worked on CHLOROMYXIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.